Visit
iwCAR-T 2022
28 Apr–01 May 2022 | Tampa, FL, USA
The 4th International Workshop on CAR-T (iwCAR-T) took place on 28 April – 1 May 2022 in Tampa, FL, with VJHemOnc as official media partner. The workshop is a high-level discussion forum for research leaders in the field of CAR-T to share their perspectives on how to place this evolving understanding in a clinical context and thereby optimize clinical care.
Session 1: CAR-T in Acute Lymphoblastic Leukemia
AUTO1, fast off-rate CD19 CAR: outcomes in adult ALL
Claire Roddie University College London, London, United Kingdom
Dual targeted approaches
Noelle Frey The University of Pennsylvania, Perlman School of Medicine, Philadelphia, PA, United States
PBCAR0191 CAR-T therapy in B-ALL
Nitin Jain The University of Texas MD Anderson Cancer Center, Houston, TX
Session 2: CAR-T in Acute Myeloid Leukemia
Targeting CD33 with CAR-T in MDS/AML
David Sallman H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
Targeting AML with CAR-T: role of myeloid cells and AML target expression
John DiPersio Washington University School of Medicine, St. Louis, MO, United States
NPM1 NK Cell CAR for AML
Rizwan Romee Dana-Farber Cancer Institute, Boston, MA, United States
T-cell based immunotherapy in AML
Marion Subklewe LMU Hospital Munich, Munich, Germany
Session 3: CAR-T in Chronic Lymphocytic Leukemia
Advances in the CLL CAR-T trial landscape/liso-cel
William Wierda The University of Texas MD Anderson Cancer Center, AL, United States
CD20-targeted CAR-T in R/R CLL
Mazyar Shadman Fred Hutchinson Cancer Research Center, Seattle, WA, United States
CART-19 with ibrutinib for the treatment of CLL
Saar Gill Perelman School of Medicine, Philadelphia, PA, United States
Session 4: Patient Focus
Patient reported outcomes in CAR-T
Heather Jim H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
Patient-reported outcomes, wearable sensor data & remote monitoring during ACT
Laura Oswald H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
Outpatient practice for CAR-T with use of remote monitoring
Jonas Paludo Mayo Clinic, Rochester, MN, United States
Session 5: CAR-T in lymphoma
Is CAR-T better than SOC in second-line LBCL?
Frederick Locke H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
Liso-cel for the treatment of B-cell lymphoma
David Maloney Fred Hutchinson Cancer Research Center, Seattle, WA, United States
Real-world evidence/determinants of response in CAR-T
Michael Jain H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
Brexucabtagene autoleucel in R/R MCL
Michael Jain H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
Prospects for upfront CAR-T for DLBCL
Julio Chavez Moffitt Cancer Center, Tampa, FL, United States
Can we cure FL with CAR-T?
Loretta Nastoupil The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Session 6: CAR-T in myeloma
Ide-cel in multiple myeloma
Nina Shah University of California, San Francisco, CA, United States
RWE in myeloma CAR-T
Doris Hansen H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
Updates on cilta-cel
Saad Usmani Memorial Sloan Kettering Cancer Center, New York, NY, United States
CAR-T ddBCMA
Matthew Frigault Massachusetts General Hospital, Boston, MA, United States
Bispecific monoclonal antibodies in myeloma: teclistamab
Maria-Victoria Mateos University Hospital of Salamanca, Salamanca, Spain
ALLO715: 'off-the-shelf' CAR-T therapy for multiple myeloma
Sham Mailankody Memorial Sloan Kettering Cancer Centre, New York City, NY, United States
Bispecifics beyond BCMA: Talquetamab
Maung Myo Htut City of Hope, Duarte, CA, United States
Roundtable Discussions
View all videos
The 4th International Workshop on CAR-T has been supported by:
VJHemOnc is intended for Healthcare Professionals only
By choosing to continue, you are confirming that you are a healthcare professional
Sign-up for our Newsletter!
Keep up to date with all the latest news with our monthly newsletter
The content of VJHemOnc is intended for healthcare professionals